- Home
- HQL vs DSGN Comparison
HQL vs DSGN Comparison
Compare HQL & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HQL | DSGN |
|---|---|---|
| Founded | 1992 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 490.5M | 579.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | HQL | DSGN |
|---|---|---|
| Price | $16.45 | $10.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $15.25 |
| AVG Volume (30 Days) | 114.0K | ★ 242.4K |
| Earning Date | 01-01-0001 | 03-09-2026 |
| Dividend Yield | ★ 11.56% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.79 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.76 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.55 | $2.62 |
| 52 Week High | $17.80 | $11.23 |
Technical Indicators
Market Signals| Indicator | HQL | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 45.78 | 50.78 |
| Support Level | $15.66 | $9.64 |
| Resistance Level | $17.51 | $11.14 |
| Average True Range (ATR) | 0.31 | 0.59 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 58.73 | 42.21 |
Price Performance
Historical ComparisonAbout HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.